One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage Plus membership.
Explore Editage Plus
Audio Papers
Ask R Discovery
Translation
Auto-sync
Collaboration
Open Accesshttps://doi.org/10.1016/j.jval.2022.09.594
Copy DOI
Export
Save
Share
Cite Journal: Value in Health |  Publication Date: Dec 1, 2022 |
 Citations: 1 |  License type: publisher-specific-oa |
Affiliation: GlaxoSmithKline (China)
In China, intravenous belimumab is listed for the treatment of SLE1; however, no evaluation of its cost-effectiveness exists. We estimated the cost-effectiveness of belimumab plus standard therapy (ST) versus ST alone, among patients with SLE, from the government payer perspective in China.
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
